Bullous Pemphigoid Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

The bullous pemphigoid market encompasses pharmaceutical products used to treat this rare autoimmune subepidermal blistering disorder, which primarily affects individuals over 60 years of age. With a 2025 valuation of around $0.645 billion, the market remains comparatively small within the broader dermatology space but commands steady demand owing to the chronic nature of the disease and the need for long-term therapy. Standard of care continues to rely on topical and systemic corticosteroids, often combined with steroid-sparing immunosuppressants.

• •Market valued at approximately $0.645 billion in 2025 with annual growth near 0.0%
• •Bullous pemphigoid is a rare autoimmune blistering disease primarily affecting the elderly
• •Current standard of care is dominated by topical and systemic corticosteroids

Demand is being lifted by aging populations in North America, Europe, and parts of Asia, which is expanding the patient pool at risk for bullous pemphigoid. Greater clinical recognition and improved diagnostic tools, including BP180/BP230 antibody testing, are also bringing more cases into the treated population. In parallel, the launch of biologic therapies such as dupilumab and other targeted immunomodulators is reshaping the treatment paradigm and beginning to drive incremental revenue growth despite the dominance of inexpensive generics.

• •Aging demographics in developed markets are increasing bullous pemphigoid incidence
• •Better diagnostic awareness and serologic testing are expanding the treated patient base
• •Approval of biologics such as dupilumab is creating a new high-value treatment segment

The market is typically segmented by drug class into corticosteroids, immunosuppressants, and biologics, with corticosteroids accounting for the largest revenue share. By route of administration, topical therapies lead, followed by oral and intravenous formulations, while therapy-line segmentation distinguishes first-line steroid use from second- and third-line immunosuppressants and biologics. North America and Europe together represent the bulk of global revenue, while Asia-Pacific is expected to grow fastest as diagnostic infrastructure and access to branded therapies improve.

• •Corticosteroids hold the largest drug-class share, with biologics the fastest-growing subsegment
• •Topical administration dominates, followed by oral and intravenous routes
• •North America and Europe lead revenue, while Asia-Pacific is the fastest-growing region

What are the recent trends and outlook?

The most significant trend is the gradual shift of treatment algorithms away from long-term high-potency steroid use toward steroid-sparing biologic regimens, particularly in patients with comorbidities such as diabetes and cardiovascular disease. Clinical pipeline activity is robust, with studies exploring JAK inhibitors, interleukin-targeting antibodies, and complement inhibitors as potential new options. Although headline growth through the forecast window remains modest near 0.0% per year, value migration toward branded biologics is expected to lift average treatment costs and reshape long-term revenue mix.

• •Treatment paradigm is shifting toward steroid-sparing biologic and targeted immunomodulator regimens
• •Pipeline activity includes JAK inhibitors, IL-targeted antibodies, and complement pathway agents
• •Average revenue per patient is expected to rise as biologics take share from generic corticosteroids